Nucleotide analogs
Phase 3
Nucleotide analogs is one of 11 therapeutic programs targeting Chronic Hepatitis b. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
11 competitors in Chronic Hepatitis B
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
PEG-IFNα
GileadPhase 3
Hepatitis B Vaccine
SanofiPhase 2
Anti-PD-1 Antibody
Boehringer IngelheimPhase 2
AHB-137
AAusper Biopharma Co., Ltd.
Phase 2
Nas
AAusper Biopharma Co., Ltd.
Phase 2
Nucleotide analogs
TThe Second Affiliated Hospital of Chongqing Medical University
Phase 3
Anti-PD-L1 Antibody
LLee's Pharmaceutical Limited
Phase 3
NA Therapy
GSKPhase 2
GST-HG141
FFujian Akeylink Biotechnology Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis b1 trial
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·120 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Nucleotide analogs. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]